The role of the Cdk9/Cyclin T1 complex in T cell differentiation

Abstract

The Cdk9/Cyclin T1 complex is very important in controlling specific differentiative pathways of several cell types, including muscle cells and neurons. We recently demonstrated the involvement of this complex in B cell activation/differentiation. To check whether the Cdk9/Cyclin T1 complex is also involved in the T cell activation/differentiation process, we isolated different T cell populations by magnetic separation, based on their surface antigens. We observed that the expression level of Cdk9/Cyclin T1 increases in effector T cells (CD27(+)), as well as in activated T cells (CD25(+)) and memory T cells (CD45RA(-)), thus suggesting a specific upregulation of the Cdk9/Cyclin T1 complex following antigen encounter. We have previously demonstrated that in B cells, Cdk9 interacts in vivo with the E2A gene products E12/E47 (members of the basic helix-loop-helix family) which are involved in differentiation. In this article, we show that this interaction also occurs in T cells. This suggests an active role for the Cdk9/Cyclin T1 complex during lymphoid differentiation, through physical binding with E12 and E47. These preliminary results suggest that the Cdk9/Cyclin T1 complex may be important in the activation and differentiation program of lymphoid cells and that its upregulation, which is due to still unknown mechanisms, may contribute to malignant transformation.

Cyclin T2: A novel miR‐15a target gene involved in early spermatogenesis

“…However, the genes affected by these cyclins are different, and among them, the pathways important for early embryogenesis and development are specifically under the control of Ccnt2 [25]. Additionally, as reported previously, cyclin T functions in various types of cell differentiation [19,40]. In this work, we confirmed that Ccnt2 was essential for muscle differentiation.…”

Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development

“…[1][2][3][4][5][6][21][22][23][24][25][26][27][28][29][30][31][32][33][34] For instance, the Cdk9-interacting cellular factors comprise MyoD, retinoblastoma protein (pRb), p53, c-Myc, hSPT5 and gp130. 5 In these cases, the Cdk9-related pathway controls the phosphorylation of the aforementioned cellular factors.…”

Targeting CDK9: a promising therapeutic opportunity in prostate cancer

“…CDK9 contributes to T lymphocyte differentiation and malignant transformation (Leucci et al 2007). Depending on tissue-specific signaling pathways, CDK9 responds to cytokines, including the tumor necrosis factor and interleukin-6 (MacLachlan et al 1998, Bellan et al 2004.…”